AVM
RUBY

Arch Venture Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Arch Venture Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-349,908
Closed -$152K – 9
2022
Q3 		$152K Hold
349,908
– – 0.02% 10
2022
Q2 		$298K Hold
349,908
– – 0.04% 9
2022
Q1 		$1.93M Hold
349,908
– – 0.28% 6
2021
Q4 		$3.39M Buy
+349,908
New +$4.85M 0.36% 6
2020
Q3 		$13.1M Hold
2,618,351
– – 65.49% 1
2020
Q2 		$15.7M Hold
2,618,351
– – 52.68% 1
2020
Q1 		$11.7M Hold
2,618,351
– – 19.67% 3
2019
Q4 		$24.9M Hold
2,618,351
– – 32.42% 1
2019
Q3 		$20.6M Hold
2,618,351
– – 22.5% 2
2019
Q2 		$41.2M Hold
2,618,351
– – 42.64% 1
2019
Q1 		$47.4M Hold
2,618,351
– – 45.77% 1
2018
Q4 		$42.1M Buy
+2,618,351
New +$47.7M 42.09% 1

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arch Venture Management's RUBY Position: Q4 2022 in Review

Arch Venture Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 349,908 shares — an estimated $152K sold.

Arch Venture Management first reported a position in RUBY in Q4 2018 and held it in 12 quarters. The position peaked at $47.4M in Q1 2019. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Arch Venture Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Arch Venture Management sold 349,908 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $152K.
  • Arch Venture Management first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 12 quarters.
  • Arch Venture Management's Rubius Therapeutics, Inc position peaked at $47.4M in Q1 2019.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Arch Venture Management's 13F filing for Q4 2022, filed 14 Feb 2023.